Skip to content Skip to left sidebar Skip to footer

Interim Clinical Considerations for Use of COVID-19 Vaccine

Interim Clinical Considerations for Use of COVID-19 Vaccine

CDC has updated the Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States to reflect the following changes in the mRNA COVID-19 vaccination schedule:

  • At the time of initial vaccination, depending on vaccine product, children ages 6 months–4 years are recommended to receive 2 or 3 bivalent mRNA vaccine doses; children age 5 years are recommended to receive 1 or 2 bivalent mRNA vaccine doses.
  • People ages 6 years and older who are unvaccinated or previously received only monovalent vaccine doses are recommended to receive 1 bivalent mRNA vaccine dose.
  • People ages 65 years and older may receive 1 additional bivalent mRNA vaccine dose.
Updated clinical guidance for individuals who are immunocompromised will be shared as soon as possible.